Media stories about Johnson & Johnson (NYSE:JNJ) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Johnson & Johnson earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.7381737368638 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Sightbox, Portland vision care startup, sells to Johnson & Johnson (oregonlive.com)
- Johnson & Johnson (JNJ) Subsidiary Janssen Research Reports New Two-Year TREMFYA (Guselkumab) Data (streetinsider.com)
- Johnson & Johnson : Sightbox, Portland vision care startup, sells to Johnson & Johnson (4-traders.com)
- Neos Therapeutics ADHD Drug Adzenys Receives Approval in US (finance.yahoo.com)
- Portland’s Sightbox sold to health care behemoth (finance.yahoo.com)
Johnson & Johnson (NYSE:JNJ) traded up 0.69% on Monday, hitting $135.38. 5,261,593 shares of the company traded hands. The stock has a market cap of $363.36 billion, a PE ratio of 22.91 and a beta of 0.79. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. The stock’s 50-day moving average is $132.72 and its 200 day moving average is $129.35.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. The firm had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.74 earnings per share. Equities research analysts expect that Johnson & Johnson will post $7.18 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th were issued a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.48%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.
Several research firms have commented on JNJ. Credit Suisse Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Friday, August 4th. Alembic Global Advisors lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. UBS AG reiterated a “buy” rating and issued a $148.00 price objective on shares of Johnson & Johnson in a research report on Thursday, August 31st. Wells Fargo & Company reiterated a “market perform” rating and issued a $135.00 price objective (up previously from $132.00) on shares of Johnson & Johnson in a research report on Thursday, July 6th. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $134.60.
In related news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.